MELVILLE, N.Y., May 14, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today provided an update on its business. "We have successfully executed against key strategic priorities since the start of the year," said Lance Alstodt, BioRestorative's Chief Executive Officer. "The most important of those were to advance our lead clinical program, BRTX-100, and expand our core preclinica ...

— New therapeutic candidate developed using Company's patented ThermoStem® platform — — Candidate has potential to serve as an adjuvant to existing pharmaceuticals that are FDA approved and marketed towards weight loss — — DMF submission and commencement of first-in-human studies targeted for before the end of 2024 — — Expanding the use of ThermoStem® may open the door to big pharma partnership opportunities — MELVILLE, N.Y., May 08, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", ...

BRTX-100研究 - BioRestorative Therapies, Inc.宣布FDA已批准对正在进行的第二阶段研究的方案进行重要修订[1] - 修订将控制组中的盐水注射替换为虚假注射，以提高研究的安全性和减少临床结果的可能性[1] - BRTX-100是公司的主要临床候选药物，旨在治疗慢性腰椎间盘疾病，目前正在进行第二阶段研究[2] 公司产品开发 - BioRestorative Therapies, Inc.开发治疗产品，主要涉及成人干细胞，包括治疗椎间盘/脊柱疾病和代谢紊乱的两个核心项目[3] - 公司正在开发ThermoStem®，一种用于治疗肥胖和代谢紊乱的细胞疗法候选药物[4]

合作关系 - BioRestorative Therapies与Galen Patient Recruitment合作，加速进行中的BRTX-100慢性腰椎间盘疾病（cLDD）第二阶段研究的患者招募[1] 治疗药物介绍 - BRTX-100是一种新型的基于细胞的治疗药物，旨在针对体内血流较少的区域[2] Galen Patient Recruitment - Galen Patient Recruitment自2006年以来通过成本效益的患者招募解决方案帮助客户推出新的医疗创新[4]

- Company is not offering shares pursuant to the registration statement - MELVILLE, N.Y., April 03, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced the filing of a registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC"). The registration statement solely covers the resale by selling securityholders of up to 2,513,686 shares of co ...

公司财务状况 - 截至2023年12月31日，公司累计亏损为1.67亿美元[194] - 2023年12月31日，公司现金、现金等价物和投资总额为1,106,5995美元[198] - 2023年，公司经营活动产生的净现金流为负$6,430,211，投资活动产生的净现金流为正$3,252,043，融资活动产生的净现金流为正$2,351,343[201] - 2023年，公司融资活动产生的净现金流较2022年增加$2,351,343，主要来源于ATM和注册直接公开发行普通股的净收益[202] 资金募集和使用 - 2023年12月31日，公司剩余ATM计划下可出售的普通股额度为5,487,000美元[195] - 2023年12月31日，公司完成了一项2,300,000股普通股和2,645,000股普通股认股权证的公开发行，募集资金净额用于临床试验、研发和一般企业和营运资金用途[194] - 2023年12月31日，公司通过ATM计划出售了132,827股普通股，募集了约62.2万美元的募集资金[195] - 2023年12月31日，公司预计有足够资金完成BRTX-100的二期临床试验，但需要大量额外资金完成拟议的BRTX-100三期临床试验和其他项目[195] - 2023年12月，公司通过注册直接公开发行出售了685,033股普通股，募集净收益约$1,831,000[200] 预期支出增加 - 2023年12月31日，公司预计未来研发支出将继续增加，特别是与棕色脂肪和椎间盘/脊柱计划相关的支出[197] - 2023年12月31日，公司预计一般和行政支出将随着扩大员工队伍、发展基础设施和承担额外成本而增加[197] - 2023年12月31日，公司预计将需要额外的股本和/或债务融资来继续运营[198] - 截至2023年12月31日，公司在ATM计划下还有约$5,487,000的普通股待售[199]

MELVILEE, N.Y., Feb. 06, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative" or the "Company") (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced it has entered into agreements with certain holders of its existing warrants exercisable for 3,351,580 shares of its common stock, in the aggregate, to exercise their warrants at a reduced exercise price of $2.33 per share, in exchange for new warrants as described below. The aggregate gross proceeds ...

— Preliminary data includes 26 and 52-week follow-up end points as part of ongoing Phase 2 trial — — Company to host webcasted conference call today at 8:30am EST — MELVILLE, N.Y., Feb. 05, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced the public availability of a poster, presented yesterday at the Orthopaedic Research Society (ORS) 2024 Annual Meeting, which de ...

BRTX-100临床试验 - BioRestorative Therapies, Inc.宣布将在2024年2月2-6日于加利福尼亚长滩举行的ORS 2024年会上展示BRTX-100正在进行的cLDD第2期临床试验的初步26-52周盲数据[1] - BRTX-100是公司的主要临床候选药物，正在进行一项第2期前瞻性、随机、双盲和对照研究，评估其在治疗cLDD中的安全性和有效性[2] ORS会议演示 - 公司将于2024年2月4日在ORS会议上展示题为“椎间盘慢性疾病的自体干细胞疗法，低氧培养间充质干细胞椎间盘内注射的初步第2期临床安全性和可行性数据”的演示[3]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _________ to _________ Commission file number: 001-37603 BIORESTORATIVE THERAPIES, INC. (Exact name of registrant as specified in its charter) Nevada 30-1341024 (Sta ...